Immunotherapy Combination for Advanced Breast Cancer

This phase 3 trial evaluates the safety and efficacy of combining atezolizumab with nab-paclitaxel in patients with triple-negative breast cancer. The study focuses on patients who have not received prior chemotherapy in the metastatic setting.

Trial Details

NCT ID
NCT06234567
Phase
Phase 3
Sponsor
Genentech, Inc.
Status
RECRUITING
Cancer Type
Breast Cancer
Locations (sample)
  • Los Angeles, California
  • Miami, Florida
  • Philadelphia, Pennsylvania
  • Atlanta, Georgia
  • Dallas, Texas

Key Eligibility Criteria

  • Age 18 years or older
  • Triple-negative breast cancer confirmed by pathology
  • No prior chemotherapy for metastatic disease
  • ECOG performance status 0-1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →